Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Gw Research Limited maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area with 5 pending office actions. These actions are distributed across 4 distinct examiners and 3 distinct art units. This level of activity indicates a diverse and active prosecution pipeline involving multiple specialized groups at the patent office.
The busiest examiner, TOWNSLEY, SARA ELIZABETH, is currently managing 2 pending office actions. This accounts for a portion of the 5 pending office actions in the portfolio. With 4 distinct examiners involved, the company's strategy must navigate the feedback of several individuals, although TOWNSLEY, SARA ELIZABETH handles the highest volume of cases.
The involvement of 3 distinct art units suggests that the company's intellectual property covers several technical sub-specialties. Practitioners should note that while the workload is spread, the busiest examiner manages 2 pending office actions, while the remaining 3 pending office actions are distributed among the other 3 distinct examiners. This distribution across 3 distinct art units requires a coordinated approach to address the varying examination standards encountered by the 4 distinct examiners.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FOWLER, ALAN JEROME | 1 | 100.0% | +0.0% |
| TRAN, ERIC | 1 | 70.8% | +23.3% |
| BAEK, BONG-SOOK | 1 | 41.7% | +69.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18560346 | RESORCINOL DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | FOWLER, ALAN JEROME | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17606370 | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | TRAN, ERIC | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17606370 | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | TRAN, ERIC | — |
| 16935005 | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | BAEK, BONG-SOOK | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 1629 | 1 |
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18560346 | RESORCINOL DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF | FOWLER, ALAN JEROME | 1691 | §103Other | Non-Final OA | — | Pending | Nov 10, 2023 |
| 17606370 | USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX | TRAN, ERIC | 1629 | §103§112 | Non-Final OA | — | Pending | Oct 25, 2021 |
| 16935005 | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | BAEK, BONG-SOOK | 1611 | §103DP | Final Rejection | — | Pending | Jul 21, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial